ChoA Pharmaceutical Co.Ltd
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral ne… Read more
ChoA Pharmaceutical Co.Ltd (034940) - Total Liabilities
Latest total liabilities as of September 2025: ₩45.09 Billion KRW
Based on the latest financial reports, ChoA Pharmaceutical Co.Ltd (034940) has total liabilities worth ₩45.09 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ChoA Pharmaceutical Co.Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how ChoA Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ChoA Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of ChoA Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YBM Net Inc
KQ:057030
|
Korea | ₩28.96 Billion |
|
Lung Ming Green Energy Technology Engineering Co Ltd
TW:3018
|
Taiwan | NT$1.07 Billion |
|
MAXST Co Ltd
KQ:377030
|
Korea | ₩120.12 Billion |
|
Thai Sugar Terminal Public Company Limited
BK:TSTE
|
Thailand | ฿2.12 Billion |
|
Cobalt Blue Holdings Ltd
PINK:CBBHF
|
USA | $3.69 Million |
|
Thitikorn Public Company Limited
BK:TK
|
Thailand | ฿297.83 Million |
|
Digital Workforce Services Oyj
HE:DWF
|
Finland | €8.52 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down ChoA Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ChoA Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ChoA Pharmaceutical Co.Ltd (2001–2024)
The table below shows the annual total liabilities of ChoA Pharmaceutical Co.Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩39.94 Billion | +12.63% |
| 2023-12-31 | ₩35.46 Billion | +8.14% |
| 2022-12-31 | ₩32.80 Billion | +7.20% |
| 2021-12-31 | ₩30.59 Billion | +27.07% |
| 2020-12-31 | ₩24.07 Billion | -28.53% |
| 2019-12-31 | ₩33.69 Billion | +12.00% |
| 2018-12-31 | ₩30.08 Billion | +2.50% |
| 2017-12-31 | ₩29.34 Billion | +7.65% |
| 2016-12-31 | ₩27.26 Billion | +0.24% |
| 2015-12-31 | ₩27.19 Billion | -2.73% |
| 2014-12-31 | ₩27.96 Billion | +38.48% |
| 2013-12-31 | ₩20.19 Billion | -5.50% |
| 2005-12-31 | ₩21.36 Billion | -1.91% |
| 2004-12-31 | ₩21.78 Billion | -37.04% |
| 2003-12-31 | ₩34.59 Billion | -6.82% |
| 2002-12-31 | ₩37.12 Billion | -16.69% |
| 2001-12-31 | ₩44.56 Billion | -- |